“CBSET strives to help innovative companies such as IlluminOss to develop new and disruptive technologies that foster paradigm-shifting improvements in patient care. In this case, for patients requiring fracture-fixation in an orthopedic trauma care unit, access to a new solution that is metal-free and can be performed in a minimally invasive manner, and not open surgery, is exciting, and our organization is proud to have contributed.”
– Peter Markham, President, CEO and co-founder of CBSET
Recent scientific papers related to CBSET’s preclinical work on this new class of orthopaedic therapy:
Biocompatibility, bone healing, and safety evaluation in rabbits with an IlluminOss bone stabilization system. McSweeney AL, Zani BG, Baird R, Stanley JR, Hayward A, Markham PM, Kopia GA, Edelman ER, Rabiner R. Journal of Orthopaedic Research. 2017 Oct;35(10):2181-2190. doi: 10.1002/jor.23532.
Evaluation of an intramedullary bone stabilization system using a light-curable monomer in sheep. Zani BG, Baird R, Stanley JR, Markham PM, Wilke M, Zeiter S, Beck A, Nehrbass D, Kopia GA, Edelman ER, Rabiner R. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2016 Feb;104(2):291-9. doi: 10.1002/jbm.b.33380.
IlluminOss Press Release: IlluminOss Medical Granted FDA Marketing Clearance for the IlluminOss® Bone Stabilization System – First De Novo Clearance by FDA’s Orthopedic Branch Granted to Company’s Novel Fracture Repair Technology
January 9, 2018
CBSET Press Release: Safety and Efficacy of New Class of Orthopedic Implant for Intramedullary Biologic Stabilization of Fractured Long Bones Studied Out to 1 Year
March 23, 2017
CBSET Press Release: New Class of Orthopedic Implants for Intramedullary Biologic Fixation of Fractured Long Bones Validated in Preclinical Models – CBSET, IlluminOss Medical Data Published in Journal of Biomedical Materials Research
April 10, 2015
Related CBSET Brochures:
CBSET GLP Preclinical Services